title: Clinical and economic analysis of allogeneic peripheral blood progenitor cell transplants: a Canadian perspective.
abstract: Allogeneic peripheral blood progenitor cell (PBPC) transplants are an alternative to BMT, although G-CSF mobilization dose, timing of pheresis and risk of GVHD are not well defined. We compared harvest characteristics, donor and recipient outcomes and costs of two PBPC transplant strategies with historical controls who received BMT. Twenty donors mobilized with four daily s.c. G-CSF doses (5 microg/kg/day) (group 1) and 20 mobilized with 10 microg/kg/day G-CSF (group 2) were compared with 20 BM controls (group 3). G-CSF and phereses were well tolerated. Four of 40 PBPC donors required femoral catheter placement. At least 2.5 x 10(6) CD34+/kg recipient weight were collected with two phereses in 19/20 donors (group 1) and 18/20 donors (group 2). Time to neutrophil (18 vs 20 vs 22 days, P = 0.02) and platelet (21 vs 24 vs 27 days, P = 0.005) engraftment was shorter in the PBPC groups (group 2 vs group 1 vs group 3) but secondary engraftment outcomes were not different. The incidence of grade 2-4 aGVHD was higher in the low-dose G-CSF group (group 1) but there was no difference in cGVHD, 100-day or 1-year survival. The mean PBPC transplant cost (group 1) at first hospital discharge was less than BM (group 3) ($34,643 vs $37,354) but the mean overall cost for both groups was similar at 100 days ($46,334 vs $46,083). Allogeneic PBPC transplant with short course, low-dose G-CSF mobilization is safe, feasible and cost equivalent to allogeneic BMT.
authors.affiliation: Department of Medical Oncology, Princess Margaret Hospital, Toronto, Ontario, Canada.
authors.forename: S
authors.initials: S
authors.lastname: Couban
authors.forename: G
authors.initials: G
authors.lastname: Dranitsaris
authors.forename: P
authors.initials: P
authors.lastname: Andreou
authors.forename: S
authors.initials: S
authors.lastname: Price
authors.forename: L
authors.initials: L
authors.lastname: Tinker
authors.forename: R
authors.initials: R
authors.lastname: Foley
authors.forename: I R
authors.initials: IR
authors.lastname: Walker
authors.forename: S
authors.initials: S
authors.lastname: Jamal
authors.forename: N
authors.initials: N
authors.lastname: Jamal
authors.forename: D
authors.initials: D
authors.lastname: Spaner
authors.forename: J
authors.initials: J
authors.lastname: Lipton
authors.forename: J
authors.initials: J
authors.lastname: Meharchand
authors.forename: H A
authors.initials: HA
authors.lastname: Messner
mesh_terms: D016026:Bone Marrow Transplantation / Q000009:adverse effects / Q000191:economics; D002170:Canada; D003365:Costs and Cost Analysis; D006085:Graft Survival; D006086:Graft vs Host Disease / Q000191:economics / Q000209:etiology; D016179:Granulocyte Colony-Stimulating Factor / Q000008:administration & dosage*; D019650:Hematopoietic Stem Cell Mobilization / Q000191:economics / Q000379:methods; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects / Q000191:economics; D006801:Humans; D010865:Pilot Projects; D014184:Transplantation, Homologous
chemical_list: D016179:Granulocyte Colony-Stimulating Factor